Home
Storia in 1 fonti
After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light | More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light in the U.S.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by…
- ·
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster…